作者
Luca Bertamini, Mariella Grasso, Mattia D'Agostino, Anna Pascarella, Patrizia Tosi, Federico Monaco, Francesco Pisani, Paola Bertazzoni, Milena Gilestro, Andrea Capra, Piero Galieni, Ombretta Annibali, Vincenzo Pavone, Stefano Molica, Sonia Ronconi, Paola Tacchetti, Pellegrino Musto, Francesca Gay, Mario Boccadoro, Stefania Oliva
发表日期
2020/11/5
来源
Blood, The Journal of the American Society of Hematology
卷号
136
期号
Supplement 1
页码范围
12-13
出版商
American Society of Hematology
简介
Background
Despite an improvement in treatment response, high-risk multiple myeloma (MM) patients (pts) experience early relapse and short disease-free survival. Together with more validated high-risk features, high levels of circulating plasma cells (high CPC) have been considered a marker of aggressive disease and poor outcome (F. Gay et al, ASH 2019; W.I. Gonsalves et al, Am J Hematol 2020). To date, there are no uniform data on the optimal cut-off predictive of clinical outcome. No prospective data on CPC are available in the setting of novel-drug clinical trials with comprehensive baseline evaluation and minimal residual disease (MRD) assessment.
Aims
1) To identify the best cut-off for CPC to predict progression-free survival (PFS);
2) to assess the impact of high CPC levels on the clinical outcome of newly diagnosed (ND)MM pts in the context of concomitant risk …
学术搜索中的文章
L Bertamini, M Grasso, M D'Agostino, A Pascarella… - Blood, The Journal of the American Society of …, 2020